Claims

1. Use of a bacteria strain belonging to the species *Lacticaseibacillus paracasei* deposited as *Lacticaseibacillus paracasei* DG I-1572 DSM 34154 in the manufacture of a medicament for treating dysbiosis of the intestinal microbiota of subjects with IBS, wherein said subjects are classified as non-constipated.

2. The use according to claim 1, wherein said subjects with IBS have elevated levels of *Collinsella aerofaciens*, *Bacteroides plebeius*, *Dorea* spp., *Ruminococcus bromii*, *Ruminococcus* spp., *Blautia* spp.

3. The use according to claim 1 or 2, wherein said elevated levels of *Collinsella aerofaciens*, *Bacteroides plebeius*, *Dorea spp.*, *Ruminococcus bromii*, *Ruminococcus spp.*, *Blautia spp.* are present in the feces of subjects with IBS in need.

4. The use according to anyone claims 1-3, wherein said bacteria is to be administered orally, preferably in the form human supplement Enterolactis® Plus capsules.

5. The use according to anyone claims 1-4, wherein said human supplement is preferably to be administered twice daily, for a period of time preferably from 4 to 24 weeks, more preferably from 8 to 12 weeks.

6. The use according to anyone of claims 1-5, wherein each of said capsules contains from $1x10^6$ a $1x10^{12}$, more preferably from $1x10^8$ to $1x10^{10}$, even more preferably from $10x10^9$ to $50x10^9$ CFU/capsule.

7. The use according to anyone of claims 1-6, wherein said bacteria is present in each of said capsules in solid form, preferably powder, dry or lyophilized.

8. The use according to anyone claims 1-7, wherein the daily dose may comprise from 1 to 4 capsules, preferably from 2 to 3 capsules/day.

9. The use according to anyone of claims 1-8, wherein said medicament is to treat abdominal symptoms in non-constipated IBS patients.